News
-
-
-
-
COMMUNIQUÉ DE PRESSE
CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2024 and Provides Business Update
CureVac announces financial results for the fourth quarter and full-year 2024 and provides a business update, including milestone achievements, financial discipline, and litigation updates -
-
-
COMMUNIQUÉ DE PRESSE
CureVac to Report Fourth Quarter and Full-Year 2024 Financial Results and Business Update on April 10, 2025
CureVac to Report Fourth Quarter and Full-Year 2024 Financial Results and Business Update on April 10, 2025. Conference call and webcast scheduled at 3 p.m. CET / 9 a.m. EST -
-
-
COMMUNIQUÉ DE PRESSE
CureVac Receives U.S. FDA IND Clearance to Initiate Phase 1 Clinical Trial for Novel mRNA-Based Precision Immunotherapy in Squamous Non-Small Cell Lung Cancer
CureVac receives U.S. FDA clearance for phase 1 trial of mRNA immunotherapy in squamous NSCLC, a novel approach combining precision therapy with pembrolizumab